Iterum Therapeutics PLC ITRM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:58 PM EDT
1.47quote price arrow down-0.03 (-2.00%)
Volume
5,193
Close
1.50quote price arrow down-0.02 (-1.32%)
Volume
96,179
52 week range
0.62 - 2.50
Loading...
  • Open1.47
  • Day High1.59
  • Day Low1.47
  • Prev Close1.52
  • 52 Week High2.50
  • 52 Week High Date11/27/23
  • 52 Week Low0.62
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap24.832M
  • Shares Out16.55M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta2.29
  • YTD % Change-23.86

KEY STATS

  • Open1.47
  • Day High1.59
  • Day Low1.47
  • Prev Close1.52
  • 52 Week High2.50
  • 52 Week High Date11/27/23
  • 52 Week Low0.62
  • 52 Week Low Date10/25/23
  • Market Cap24.832M
  • Shares Out16.55M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta2.29
  • YTD % Change-23.86

RATIOS/PROFITABILITY

  • EPS (TTM)-2.64
  • P/E (TTM)-0.57
  • Fwd P/E (NTM)-0.63
  • EBITDA (TTM)-43.787M
  • ROE (TTM)-355.35%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-278,729.69%
  • Debt To Equity (MRQ)-296.05%

EVENTS

  • Earnings Date08/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Iterum Therapeutics PLC

 

Profile

MORE
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent...
Brenton Ahrens
Independent Chairman of the board
Corey Fishman
President, Chief Executive Officer, Director
Judith Matthews
Chief Financial Officer
Address
Fitzwilliam Court
1st Floor, Leeson Close, Dublin 2
Dublin
D02 YW24
Ireland